Higashiyama, Masaaki http://orcid.org/0000-0002-3206-4055
Sugita, Akira
Koganei, Kazutaka
Wanatabe, Kenji
Yokoyama, Yoko
Uchino, Motoi
Nagahori, Masakazu
Naganuma, Makoto
Bamba, Shigeki
Kato, Shingo
Takeuchi, Ken
Omori, Teppei
Takagi, Tomohisa
Matsumoto, Satohiro
Nagasaka, Mitsuo
Sagami, Shintaro
Kitamura, Kazuya
Katsurada, Takehiko
Sugimoto, Ken
Takatsu, Noritaka
Saruta, Masayuki
Sakurai, Toshiyuki
Watanabe, Kazuhiro
Nakamura, Shiro
Suzuki, Yasuo
Hokari, Ryota
Funding for this research was provided by:
Ministry of Health, Labour and Welfare
Article History
Received: 29 March 2019
Accepted: 8 April 2019
First Online: 20 April 2019
Change Date: 7 August 2019
Change Type: Correction
Change Details: Management of elderly ulcerative colitis in Japan
Compliance with ethical standards
:
: Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: (1) those from which the authors have received individually any income, honoraria or any other types of remuneration: Abbvie Inc., EA Pharma Co., Ltd., Janssen Pharmaceutical K.K., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd, Yakult Honsha Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Pfizer Inc., Takeda Pharmaceutical Company Limited, and Zeria Pharmaceutical Co., Ltd.; and (2) those from which the academic institutions of the authors received support (commercial/academic cooperation): Abbvie Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., JIMRO Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Kayaku Co., Ltd., and Takeda Pharmaceutical Company Limited.